Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,521,431
Introduction
U.S. Patent 4,521,431, granted on June 4, 1985, to Eli Lilly and Company, primarily covers a specific ligand-binding assay for measuring Thyroid-Stimulating Hormone (TSH) levels. Its innovation lies in the use of monoclonal antibodies specific to human TSH, enabling more sensitive and specific diagnostic tests for thyroid disorders. This patent has played a crucial role in the development of modern immunoassays and has influenced subsequent patent filings in the domain of hormone detection and immunodiagnostics.
Scope of the Patent
The patent’s scope revolves around the methodology and compositions used for detecting TSH via immunoassay techniques involving monoclonal antibodies. The core elements include:
- The preparation of monoclonal antibodies specific to human TSH.
- The use of these antibodies in an immunometric assay format, allowing the quantification of TSH in biological samples.
- The provision of a diagnostic method with increased sensitivity and specificity for thyroid functional status.
Importantly, the scope extends to the composition of the monoclonal antibody preparations and the methods of assay implementation. It does not broadly claim the concept of immunoassays but is limited to TSH detection via monoclonal antibodies created and used as described.
Claims Analysis
Claims Overview (Primary Focus on Claims 1-10):
-
Claim 1: Defines an immunoassay for TSH detection utilizing a monoclonal antibody that specifically binds to human TSH, establishing the fundamental method.
-
Claims 2-4: Specify details about the monoclonal antibody — including its affinity, binding specificity, and preparation process.
-
Claims 5-6: Cover the use of the monoclonal antibody in competitive or non-competitive assay formats, emphasizing assay sensitivity.
-
Claims 7-8: Pertains to particular labeling methods (e.g., radioisotopes) and the use of certain buffer compositions for optimal assay performance.
-
Claims 9-10: Address the application in medical diagnostics, including the measurement of TSH levels in patient samples and interpretation for clinical purposes.
Scope of Claims:
The claims tightly focus on monoclonal antibody-based immunoassays specific for human TSH, defining not just the general approach but specific properties of the antibodies and methods of use. The patent emphasizes both the composition of the monoclonal antibodies and their application in diagnostic assays.
Limitations:
- Does not claim methods for detecting other hormones or proteins unrelated to TSH.
- Limits to assays employing monoclonal antibodies with the described properties.
- The patent's claims are confined to specific assay formats and antibody preparations, not broader immunodiagnostic technologies.
Patent Landscape
Historical Context and Significance:
At the time of filing in 1983 (application no. 06/480,674), monoclonal antibody technology was emerging rapidly after Köhler and Milstein's breakthrough in 1975. Eli Lilly’s patent was among the pioneering claims protecting monoclonal antibody-based hormonal assays, specifically for TSH, a critical diagnostic marker for thyroid disorders.
Patent Family and Related Patents:
-
Extension and Continuations: Several subsequent patents cite this patent in the context of improved immunoassay formats, alternative antibody production methods, and assay kits.
-
Competitor Patents: The landscape features patents from other players like Abbott, Amersham (GE Healthcare), and Roche, who have developed competing TSH assay patents. Many of these build upon the foundational principles established here, focusing on assay automation, label development, or antibody engineering.
-
Modern Developments: Advances include recombinant antibody techniques, multiplex assays, and biosensor integrations. These developments, however, often cite or build upon the core principles of monoclonal antibody specificity for TSH, as pioneered in this patent.
Legal Status and Patent Expiry:
- The patent expired on June 4, 2002, after the standard 17-year term from issuance, opening the field to generic assay manufacturers.
- The expiration has led to widespread clinical adoption of TSH immunoassays based on the foundational technology.
Patent Landscape Summary:
- The patent set the cornerstone for monoclonal antibody-based TSH assays.
- It greatly influenced subsequent innovations, with many patents citing its claims.
- The field has since evolved with recombinant antibodies and novel detection platforms, but the scope remains anchored in the principles established by this patent.
Implications for Industry and Innovation
The patent’s scope provided the pioneering framework for clinical TSH testing, enabling:
- The commercialization of highly sensitive and specific immunoassays.
- The entry of multiple diagnostic companies into the thyroid hormone testing market.
- The foundation for subsequent innovations in hormone immunoassays and biomarker detection.
Its claims have become a standard reference point in patent examinations and litigation concerning hormone assays and monoclonal antibody applications.
Conclusion
U.S. Patent 4,521,431 delineates a focused scope—covering the use of monoclonal antibodies for TSH detection—encapsulating both the composition and methods of assay implementation. Its claims solidified a transformative approach in thyroid diagnostics, spawning a broad patent landscape that shaped subsequent innovations. The patent’s expiry facilitated broader access, industrial competitiveness, and technological evolution in immunodiagnostics.
Key Takeaways
- The patent significantly advanced monoclonal antibody applications in clinical diagnostics, specifically for TSH.
- The claims are concentrated on specific antibodies and assay formats, limiting broad claims but establishing a critical technological foundation.
- The patent landscape is characterized by subsequent innovations that have built upon this patent’s principles, including recombinant antibodies and multiplex testing.
- The patent's expiration has democratized access, enabling diverse companies to develop and commercialize TSH assays.
- For patent strategists, understanding the core claims and scope aids in evaluating freedom-to-operate within the immunoassay domain.
FAQs
1. Does U.S. Patent 4,521,431 cover all TSH assays?
No. It specifically claims monoclonal antibody-based immunoassays developed according to the described methods and properties. It does not extend to all TSH detection methods or other assay formats.
2. Are monoclonal antibodies still protected from this patent?
No. The patent expired in 2002, allowing others to produce monoclonal antibodies for TSH without infringing.
3. Can I develop a TSH assay using recombinant antibodies now?
Yes. Post-expiry, innovations like recombinant antibodies are permissible, provided they do not infringe other active patents.
4. How has this patent influenced current TSH diagnostic technologies?
It set the foundational approach for monoclonal antibody immunoassays, with modern methods evolving that build upon its principles, such as automation and multiplex analyte detection.
5. Are there any ongoing patent litigations related to this patent?
Typically, given patent expiry over 20 years ago, active litigations are unlikely. However, related patents citing this patent may still be litigated individually.
References
- U.S. Patent No. 4,521,431. Eli Lilly and Company. (Granted June 4, 1985).
- Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495-497.
- Patent landscape reports on immunoassays for thyroid hormones, various industry analyses (2010–2022).
